Ascendiant initiated coverage of Cyclo Therapeutics with a Buy rating and $2.60 price target. Cyclo is a drug company specializing in cyclodextrin-based therapies for neuro-degenerative diseases, including Niemann-pick type C and Alzheimer’s disease, the analyst tells investors in a research note. The firm says the patient cultivation of the company’s cyclodextrin platform brings it close to breakthrough therapies.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTH: